GLUE vs ARVN vs KYMR

For growth investors, Monte Rosa Therapeutics, Inc.

(GLUE) is the stronger pick with 63. 5% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Monte Rosa Therapeutics, Inc. (GLUE) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +64. 1%, compared to -91. 3% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: KYMR returned +149. 4% versus ARVN's -55. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 0. 90β versus Monte Rosa Therapeutics, Inc. 's 1. 30β — meaning GLUE is approximately 45% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 17% for Monte Rosa Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Monte Rosa Therapeutics, Inc.

(GLUE) is pulling ahead at 63. 5% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Arvinas, Inc. grew EPS 53. 8% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, ARVN leads at 26. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arvinas, Inc.

(ARVN) is the more profitable company, earning -30. 8% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps -30. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARVN leads at -43. 8% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), +149. 4% 10Y return). Both have compounded well over 10 years (KYMR: +149. 4%, GLUE: -19. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GLUE is a small-cap high-growth stock; ARVN is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.